Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 157,346 shares, a growth of 52.5% from the February 26th total of 103,151 shares. Based on an average daily volume of 507,332 shares, the short-interest ratio is currently 0.3 days. Currently, 4.2% of the shares of the stock are short sold.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors bought a new stake in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned approximately 0.40% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Capstone Therapeutics Stock Down 3.5%

CAPS stock opened at $0.63 on Friday. The firm has a 50-day moving average price of $0.64 and a 200-day moving average price of $0.86. Capstone Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.29. The company has a current ratio of 0.95, a quick ratio of 0.35 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $5.75 million, a P/E ratio of -0.67 and a beta of -1.23.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.